| Item Type | Name |
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
|
Academic Article
|
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
|
|
Concept
|
Maximum Tolerated Dose
|
|
Academic Article
|
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-?? and p70s6k, in patients with advanced solid tumors.
|
|
Academic Article
|
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
|
|
Academic Article
|
Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.
|
|
Academic Article
|
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
|
|
Academic Article
|
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
|
|
Academic Article
|
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
|
|
Academic Article
|
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.
|
|
Academic Article
|
A first-in-human study of conatumumab in adult patients with advanced solid tumors.
|
|
Academic Article
|
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.
|
|
Academic Article
|
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.
|
|
Academic Article
|
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.
|
|
Academic Article
|
A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.
|
|
Academic Article
|
Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement.
|
|
Academic Article
|
Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.
|
|
Academic Article
|
Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors.
|
|
Academic Article
|
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
|
|
Academic Article
|
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.
|
|
Academic Article
|
MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
|
|
Academic Article
|
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
|
|
Academic Article
|
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors.
|
|
Academic Article
|
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
|
|
Academic Article
|
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
|
|
Academic Article
|
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
|
|
Academic Article
|
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.
|
|
Academic Article
|
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
|
|
Academic Article
|
Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies.
|
|
Academic Article
|
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
|
|
Academic Article
|
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.
|
|
Academic Article
|
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
|
|
Academic Article
|
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
|
|
Academic Article
|
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
|
|
Academic Article
|
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.
|
|
Academic Article
|
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.
|
|
Academic Article
|
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
|
|
Academic Article
|
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
|
|
Academic Article
|
A phase 1 study of anti-TGF? receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
|
|
Academic Article
|
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
|
|
Academic Article
|
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
|
|
Academic Article
|
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.
|
|
Academic Article
|
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
|
|
Academic Article
|
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors.
|
|
Academic Article
|
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
|
|
Academic Article
|
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.
|
|
Academic Article
|
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers.
|
|
Academic Article
|
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
|
|
Academic Article
|
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
|
|
Academic Article
|
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
|
|
Academic Article
|
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
|
|
Academic Article
|
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
|
|
Academic Article
|
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
|